CRISPR Therapeutics AG

CRISPR Therapeutics AG

CRISPR Therapeutics AG

Date Founded



Baarerstrasse 14, Zug, 6300, CHE

Type of Company


Employees (Worldwide)




Company Description

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.

Executives & Employees


Chief Executive Officer & Director

Senior Vice President & Chief Financial Officer

Secretary & General Counsel

Chief Business Officer

Executive Vice President & Head of Research & Development

Head-Human Resources

Head of Immuno-Oncology Research & Translation

Head of Intellectual Property

Board of Directors

Founder at CRISPR Therapeutics AG

Scientific Co-Founder at Spark Therapeutics, Inc.

General Partner, Washington DC at New Enterprise Associates

Executive Vice President & Chief Financial Officer at Discover Financial Services

Chief Executive Officer at Rubius Therapeutics, Inc.

Managing Director, Chairman at Versant Venture Management LLC

Partner at SR One Ltd.

Chief Executive Officer & Director at CRISPR Therapeutics AG

Secretary & General Counsel at CRISPR Therapeutics AG

Paths to CRISPR Therapeutics AG
Potential Connections via
Relationship Science
CRISPR Therapeutics AG
Owners & Shareholders
Details Hidden

Versant Venture Management specializes in early-stage investments in medical devices, biotechnology and pharmaceuticals, healthcare services and healthcare information technology. The firm may also consider later-stage opportunities

Details Hidden

Nikko AMA's investment advice is based on the objectives and terms set out in individual client investment management agreements, relevant fund prospectuses or offering memoranda. Specialist teams throughout the Nikko AM Group's global network are dedicated to providing analysis on macro-economic factors, specific asset classes, strategies and styles. The firm's investment strategy group provides macro-economic insight on factors influencing markets, working in conjunction with investment professionals throughout the group's global network. Equity analysts are assigned responsibilities based on geographic regions, sectors or investment styles. The Nikko AM Group's general approach focuses on fundamental bottom up analysis; although it will vary depending on specific requirements of the investment strategy pursued and is tailored accordingly.

Details Hidden

ARK Investment Management is a registered investment adviser and privately held investment firm, specializing in thematic investing. The firm is rooted in over thirty years of experience in identifying and investing in disruptive innovations that enable outsized growth as industries transform. Through its open source research process, ARK is able to identify companies that it believes are leading and benefiting from disruptive cross-sector forces and changing how the world works.

Recent Transactions
Details Hidden

CRISPR Therapeutics AG issued USD Common Shares

Details Hidden

CRISPR Therapeutics AG issued USD Common Shares

Details Hidden

CRISPR Therapeutics AG issued Common Shares

Transaction Advisors
Escrow Agent

Advised onCRISPR Therapeutics AG issued USD Common Shares


Advised onCRISPR Therapeutics AG issued USD Common Shares


Advised onCRISPR Therapeutics AG issued USD Common Shares

Chair, Life Sciences Practice

Advised onCRISPR Therapeutics AG issued USD Common Shares

Legal Advisor

Advised onCRISPR Therapeutics AG issued USD Common Shares


Advised onCRISPR Therapeutics AG issued USD Common Shares

Advisors & Consultants

Founder at Yumanity Therapeutics, Inc.

Senior Advisor

Former Medical Director at Genzyme Corp.


Managing Director at Westwicke Partners LLC


Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal year 2012, Bayer employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2 billion, R&D expenses to €3 billion.

Key Stats and Financials As of 2018
Market Capitalization
Total Enterprise Value
Earnings Per Share
Net Profit
Total Debt
Total Equity
Enterprise Value Sales
TEVNet Income
Debt TEV
Details Hidden

Versant Venture Management specializes in early-stage investments in medical devices, biotechnology and pharmaceuticals, healthcare services and healthcare information technology. The firm may also consider later-stage opportunities

Details Hidden

New Enterprise Associates (NEA) focuses on investments in the technology and healthcare sectors. The firm's investment strategy spans all stages of a company's growth, from seeding innovations in emerging markets to funding early-stage companies in high-growth markets to fueling the growth of market leaders. NEA actively invests in emerging markets, with emphasis on India and China.NEA's investments in the healthcare sector focus on companies that address unmet or underserved clinical needs and that combine improved clinical outcomes with lower costs to the market. The firm targets three areas including biopharmaceuticals, medical devices and healthcare services. The firm has a history of partnering with companies that have pioneered transformative innovations in healthcare, such as balloon angioplasty and laparoscopic surgeryWithin the technology sector, NEA focuses on investments in the electronics, consumer technology, enterprise mobility, virtualization, tech-enabled services, SaaS and cloud computing industries.

Details Hidden

Abingworth is an active, long-term manager which invests exclusively in companies in the life sciences and healthcare sectors including biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, medical devices, diagnostics, instrumentation. Their geographic focus is primarily on the US, UK and Europe.The firm seeks to invest USD 15-30 million in small-cap early and late-stage venture, growth equity and public biotechnology companies with strong management and novel technology that offers a significant improvement over current approaches.Abingworth takes minority or majority stakes in their investee companies, seeking to build relationships with management to create world-class companies.They typically hold an investment for three to eight years.

University of California Investment Services & Portfolio Management

The University is governed by The Regents, which under Article IX, Section 9 of the California Constitution has "full powers of organization and governance" subject only to very specific areas of legislative control. The article states that "the university shall be entirely independent of all political and sectarian influence and kept free therefrom in the appointment of its Regents and in the administration of its affairs." Board Membership Article IX, Section 9 was drafted in 1878 after a decade of political conflict demonstrated the importance of sheltering the university from shifting political winds. The board consists of 26 members: 18 regents are appointed by the governor for 12-year terms One is a student appointed by the Regents to a one-year term Seven are ex officio members -- the Governor, Lieutenant Governor, Speaker of the Assembly, Superintendent of Public Instruction, president and vice president of the Alumni Associations of UC and the UC president. In addition, two faculty members -- the chair and vice chair of the Academic Council -- sit on the board as non-voting members. Board Officers The Governor is officially the president of the Board of Regents; however, in practice the presiding officer of the Regents is the Chairman of the Board, elected from among its body for a one-year term, beginning July 1. The current Chairman is Regent Sherry Lansing. The Vice Chairman is Regent Bruce Varner. The Regents appoints Officers of The Regents: the General Counsel; the Chief Investment Officer; the Secretary and Chief of Staff; and the Chief Compliance and Audit Officer. Former Regents Here is a list of individuals who have served as Regents of the University of California: Former Regents Committees and Meetings The Regents operates through 10 standing committees: Compliance and Audit, Compensation, Educational Policy, Finance, Governance, Grounds and Buildings, Health Services, Investments, Long Range Planning, and Oversight of the Department of Energy Laboratories. The Regents meets six times a year every other month in two-day meetings

Orgenesis, Inc. Biotechnology | Germantown, MD

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CT) segments. The CDMO segment through MaSTherCell, comprises of comprehensive services from cell therapy development through cell therapy manufacturing for and companies that provide end-to-end solution. The CT segment includes a technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and trans-differentiating them into pancreatic beta cell-like insulin-producing cells. The company was founded on June 5, 2008 by Sarah Ferber and is headquartered in Germantown, MD.

MaxCyte, Inc. Industrial Machinery & Manufacturing | Gaithersburg, Maryland

MaxCyte, Inc. enages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include MaxCyte STX, MaxCyte VLX, and MaxCyte GT. The company was founded by Douglas A. Doerfler and is headquartered in Gaithersburg, MD.

Celgene Corp. Pharmaceuticals

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Novartis AG Pharmaceuticals - Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

REGENXBIO, Inc. Biotechnology - ROCKVILLE, MD

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by CRISPR Therapeutics AG. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of CRISPR Therapeutics AG's profile does not indicate a business or promotional relationship of any kind between RelSci and CRISPR Therapeutics AG.